Bridge the Gaps in Analytical Technology, Modelling, Regulatory Experience & Internal Culture to Define CQAs, Enable Feedback Control and Real Time Optimization

The time has come to remove the pharmaceutical industry’s reliance on archaic off-line testing and embrace the cost and speed-to-market savings of online control and real-time product quality.

The PAT market is projected to reach USD 4.96 Billion by 2027, spurred on by the recent ICH Q14/ Q2 (R2) guidelines, there has never been a more opportune moment to leverage regulator's support of QbD, real-time control, and process intervention to achieve meaningful business impact in your organization, through reduced downtime, manufacturing footprint, ease of scale-up and product consistency for approval.

Whether you’re applying in small molecules, biologics, or ATMP, bridge the gap in technology, culture, or regulatory experience that is the bottleneck to your organization saving an average 50% reduction in process cycle time and winning speed to market, with the strategical implementation of smart process analytical technologies and quality by control (QbC).

Join a senior community of experts in process development, manufacturing, regulatory & quality to understand how to monitor critical quality attributes with reactive and predictive control systems and discover novel PAT technologies as the industry moves the needle toward realizing real-time release.